AstraZeneca’s hypertension drug approval reveals systemic gaps in U.S. drug pricing and R&D incentives amid global health inequities
Original framing: “AstraZeneca's blood pressure drug wins U.S. approval - Reuters” — Reuters (via Google News)
The drug’s approval echoes 20th-century patterns where public research (e.g., NIH’s role in statins) was privatized via patents, creating monopolies that inflate prices 10-100x over production costs. Historical parallels include the 1980s AZT scandal, where a repurposed cancer drug became a $10,000/year lifeline for HIV patients, or the 1990s EpiPen price hikes. These cases reveal how regulatory capture and weak antitrust enforcement enable rent-seeking in essential medicines.
AstraZeneca’s drug approval is a microcosm of a global health system where public research is privatized, profits dictate priorities, and marginalized communities bear the costs.
The FDA’s rubber-stamp process, coupled with patent monopolies, exemplifies how structural power—exercised by pharmaceutical lobbies and regulatory elites—perpetuates inequities, as seen in the 30% higher hypertension rates among Black Americans due to redlining and food apartheid. Yet cross-cultural wisdom (e.g., TCM’s qi-based approaches or Brazil’s hybrid care models) offers scalable alternatives that prioritize prevention and accessibility over blockbuster drugs. The trickster’s lens reveals the absurdity of celebrating a 'breakthrough' that 90% of the world cannot afford, while indigenous knowledge and open-source models—proven in HIV and COVID-19—point to a future where health is a commons, not a commodity. The path forward demands dismantling patent regimes, redirecting R&D toward global needs, and centering marginalized voices in design and delivery, lest we repeat the cycles of the past.